Targeting KRAS in Pancreatic Cancer

被引：11
|
作者：
Cowzer, Darren [1 ]
Zameer, Mohammed [1 ]
Conroy, Michael [1 ]
Kolch, Walter [2 ,3 ]
Duffy, Austin G. [1 ]
机构：
[1] Mater Misericordiae Univ Hosp, Dept Med Oncol, Dublin D07R2WY, Ireland
[2] Univ Coll Dublin, Sch Med, Syst Biol Ireland, Belfield D04E1W1, Dublin, Ireland
[3] Univ Coll Dublin, Conway Inst Biomol & Biomed Res, Belfield D04E1W1, Dublin, Ireland
来源：
JOURNAL OF PERSONALIZED MEDICINE | 2022年 / 12卷 / 11期
基金：
爱尔兰科学基金会;
关键词：
KRAS; pancreas cancer; targeted therapy; CELL LUNG-CANCER; ONCOGENIC KRAS; SOLID TUMORS; AMG; 510; INHIBITOR; THERAPY; COMBINATION; ADENOCARCINOMA; IMMUNOTHERAPY; GEMCITABINE;
D O I：
10.3390/jpm12111870
中图分类号：
R19 [保健组织与事业（卫生事业管理）];
学科分类号：
摘要：
Pancreatic cancer is mainly driven by mutations in the KRAS oncogene. While this cancer has shown remarkable therapy resistance, new approaches to inhibit mutated KRAS, KRAS activators and effectors show promise in breaking this therapeutic deadlock. Here, we review these innovations in therapies that target RAS signaling in pancreatic cancer from a clinical point of view. A number of promising approaches are currently in clinical trials or in clinical development. We focus on small-molecule drugs but also discuss immunotherapies and tumor vaccines.
引用
收藏
页数：11
相关论文
共 50 条
  • [11] Targeting KRAS mutations in pancreatic cancer: opportunities for future strategies
    Linehan, Anna
    O'Reilly, Mary
    McDermott, Ray
    O'Kane, Grainne M.
    FRONTIERS IN MEDICINE, 2024, 11
  • [12] Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer
    Sushrut Kamerkar
    Valerie S. LeBleu
    Hikaru Sugimoto
    Sujuan Yang
    Carolina F. Ruivo
    Sonia A. Melo
    J. Jack Lee
    Raghu Kalluri
    Nature, 2017, 546 : 498 - 503
  • [13] Targeting lipid metabolism disrupts KRAS oncogenesis in pancreatic cancer
    Arora, Neha
    Liang, Hong
    Reed, Alex
    Chang, Jeffrey T.
    Cravatt, Benjamin F.
    Zhou, Yong
    CANCER RESEARCH, 2024, 84 (06)
  • [14] Targeting KRAS selectively induce metabolic reprogramming in pancreatic cancer
    Shiekh, Laiba
    Cheung, Matthew
    Zheng, Linyuhui
    Marlette, Erica
    Ezeh, Chiamaka J.
    Conde, Don-Gerard
    Nwosu, Zeribe C.
    CANCER RESEARCH, 2024, 84 (17)
  • [15] Therapeutic targeting of oncogenic KRAS in pancreatic cancer by engineered exosomes
    Whiteside, Theresa L.
    TRANSLATIONAL CANCER RESEARCH, 2017, 6 : S1406 - S1408
  • [16] Targeting KRAS for diagnosis, prognosis, and treatment of pancreatic cancer: Hopes and realities
    Bournet, Barbara
    Buscail, Camille
    Muscari, Fabrice
    Cordelier, Pierre
    Buscail, Louis
    EUROPEAN JOURNAL OF CANCER, 2016, 54 : 75 - 83
  • [17] Targeting KRAS-regulated metabolic activities in pancreatic cancer.
    Bryant, Kirsten L.
    Hobbs, G. Aaron
    Der, Channing J.
    MOLECULAR CANCER RESEARCH, 2020, 18 (05) : 21 - 22
  • [18] Targeting Mitochondrial Function and Biogenesis in KRAS-Dependent Pancreatic Cancer
    Badejo, Adeleke Modupe
    McCreary, Jordan
    Szlavich, Ellyssa
    True, Heather
    Serrato, Ana
    Love, Quintin
    Malhotra, Ashim
    FASEB JOURNAL, 2017, 31
  • [19] In Silico Identification of Dysregulated miRNAs Targeting KRAS Gene in Pancreatic Cancer
    Garibaldi-Rios, Asbiel Felipe
    Figuera, Luis E.
    Zuniga-Gonzalez, Guillermo Moises
    Gomez-Meda, Belinda Claudia
    Garcia-Verdin, Patricia Montserrat
    Carrillo-Davila, Irving Alejandro
    Gutierrez-Hurtado, Itzae Adonai
    Torres-Mendoza, Blanca Miriam
    Gallegos-Arreola, Martha Patricia
    DISEASES, 2024, 12 (07)
  • [20] Targeting KRAS in cancer
    Singhal, Anupriya
    Li, Bob T.
    OReilly, Eileen M.
    NATURE MEDICINE, 2024, 30 (03) : 969 - 983
12345